Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Ossur Hf : Q3 Results 2016


Posted on: 26 Oct 16

Announcement from Össur hf. No. 88/2016

Reykjavík, 26 October 2016

ÖSSUR Q3 RESULTS 2016

Highlights Q3 2016

  • Sales amounted to USD 129 million compared to USD 117 million in Q3 2015, corresponding to local currency growth of 11% and 5% organic growth.
  • Gross profit amounted to USD 81 million or 63% of sales, compared to USD 74 million or 63% of sales in Q3 2015.
  • EBITDA amounted to USD 24 million or 19% of sales compared to USD 25 million or 22% of sales in Q3 2015.
  • Net profit amounted to USD 13 million or 10% of sales, compared to USD 14 million or 12% of sales in Q3 2015.
  • Cash generated by operations amounted to USD 27 million or 21% of sales, compared to USD 23 million or 20% of sales in Q3 2015.
  • On September 1, Össur acquired Medi Prosthetics. The income statement for Q3 2016 therefore includes Medi Prosthetics for the month of September only.
  • Össur acquired 301,621 of own shares in Q3 2016 for approximately USD 1.2 million.

Financial Guidance for 2016

We are revising the financial guidance for the full year of 2016. Due to recent acquisitions we are upgrading sales growth measured in local currency from the range of 7-9% to the range of 8-10%. Adjusted EBITDA margin is now expected to be approximately 19%. The downwards revision of the EBITDA margin is mainly due to adverse currency movements, specifically the strengthening of the ISK, and impact from the Medi Prosthetics acquisition which is expected to be temporary while the acquired business is being integrated and synergies realized. The revised guidance is as follows:

  • Sales growth LCY in the range of 8-10% (previously 7-9%)
  • Organic sales growth LCY in the range of 3-5% (unchanged)
  • Adjusted EBITDA margin around 19% of sales (previously 20-21%)
  • Capital expenditures 5% of sales (unchanged)
  • Effective tax rate around 26% (unchanged)

  

Jon Sigurdsson, President & CEO, comments:

"The sales growth in the quarter was good. Prosthetics growth was excellent, driven by bionics and newly launched products. In September we acquired Medi Prosthetics. Medi Prosthetics is a global provider of mechanical limb prosthetic components. This acquisition enables us to take another step to complete our prosthetics offering and further strengthen our global market position. Due to adverse currency movements, mainly the strengthening of the ISK, and temporary impact from the Medi Prosthetics acquisition we have revised our guidance for the full year."


Conference Call

Össur will host a conference call on Thursday October 27 2016 at 9:00 CET/ 7:00 GMT/ 3:00 EDT.                           
To participate in the call please dial: Europe: + 45 3544 5580, +44 (0) 203 364 5374 or +46 (0) 8 505 564 74,                     
The United States: + 1 855 753 2230, Iceland: +354 800 7417

GlobeNewswire
globenewswire.com

Last updated on: 27/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.